Lv7
5010 积分 2021-01-10 加入
A first-in-human phase I dose-escalation study of MK-1496, first-in-class orally available novel PLK1 inhibitor, in patients with advanced solid tumors
3天前
已关闭
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity
10天前
已完结
Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia
10天前
已完结
Discovery of ZX079 as a Dual PROTAC Degrader Targeting BRD4/CBP in Acute Myeloid Leukemia
10天前
已完结
Discovery of XYD270 as a Potent, Selective, and Orally Efficacious BRD9 PROTAC for Cancer Therapy
10天前
已完结
Discovery of a Highly Potent and Efficient BRD9 Degrader with Strong In Vivo Antitumor Activity
10天前
已完结
A renaissance in targeting the PI3K/AKT/mTOR pathway
1个月前
已完结
A multicenter phase Ia study of AbGn-107, a novel antibody-drug conjugate, in patients with advanced gastrointestinal cancer
1个月前
已完结
Structural and functional complexity of HSP90 in cellular homeostasis and disease
1个月前
已完结
ADAM9: an updated view of its biology and pathology
1个月前
已完结